Titrating fill volume, dwell time, and daily exchange count in continuous ambulatory peritoneal dialysis — balancing clearance, ultrafiltration, and patient comfort
Peritoneal dialysis exploits the peritoneum — a ~1–2 m² vascularized membrane lining the abdominal cavity — as a natural dialysis filter. Instilling more dialysate stretches this membrane over a larger effective surface, recruiting additional capillary exchange area and improving both diffusive clearance and convective ultrafiltration. But the abdominal cavity is a closed compliant space: every additional milliliter raises intra-abdominal pressure (IAP), and IAP is the single biggest modifiable driver of mechanical complications in CAPD.
The peritoneal membrane behaves like a three-pore system: small solute pores (urea, creatinine, potassium) dominate diffusive transport, while ultra-small aquaporin channels and larger inter-endothelial pores govern water and macromolecule movement. Diffusive clearance of small solutes is proportional to the effective peritoneal surface area in contact with dialysate and the concentration gradient between blood and dialysate.
Increasing fill volume does two things simultaneously:
• Recruits more peritoneal surface area — the abdominal cavity is not a rigid box; a larger fill unfolds more mesothelial surface against loops of bowel and the parietal peritoneum, increasing the area available for solute exchange • Dilutes the dialysate solute concentration for a given mass transferred, which can transiently slow the diffusion gradient early in the dwell, but the net effect across a full dwell is still higher total clearance with higher fill volume
Because of this, raising fill volume from 2.0 L to 2.5 L in an adult of average body size typically increases per-exchange creatinine clearance meaningfully — but the marginal clearance gained per additional liter diminishes as the peritoneal surface area approaches saturation.
The peritoneal cavity is a closed, compliant space bounded by the diaphragm, abdominal wall musculature, and pelvic floor. Instilling dialysate raises intra-abdominal pressure roughly in proportion to fill volume, modified by patient position (supine IAP is markedly lower than standing or sitting IAP for the same fill) and abdominal wall compliance.
Clinically relevant consequences of elevated IAP include:
• Mechanical discomfort — sensation of fullness, bloating, early satiety from gastric compression • Increased dialysate leaks — pericatheter leaks and pleuroperitoneal leaks (hydrothorax) become more likely as pressure rises • Hernia formation — inguinal, umbilical, and incisional hernias are more common with chronically elevated IAP, particularly in the early weeks after catheter placement before the abdominal wall has healed • Reduced diaphragmatic excursion — very high fills can compromise respiratory mechanics, especially problematic in patients with pre-existing pulmonary disease
Because IAP scales with fill volume relative to the patient's own abdominal cavity capacity, the same absolute fill volume (e.g., 2.5 L) that is well tolerated in a large-framed patient may produce clinically significant pressure elevation in a smaller patient — which is precisely why fill volume prescriptions are individualized rather than fixed.
A practical bedside marker: if a patient reports new or worsening fullness, dyspnea, or a bulge at the catheter exit site or umbilicus shortly after increasing fill volume, intra-abdominal pressure — not solute clearance — is usually the limiting factor, and volume should be reduced or increased more gradually.
Because intra-abdominal pressure depends on fill volume relative to abdominal cavity capacity — not on fill volume in isolation — CAPD prescriptions are individualized to body size, most commonly approximated by body surface area (BSA) or, in pediatrics, body weight. A fill volume that is conservative for a large-framed patient may already be near the comfort ceiling for a small-framed patient.
Body surface area correlates reasonably well with both peritoneal membrane surface area and abdominal cavity compliance, making it a practical — if imperfect — anchor for initial fill volume selection. In practice, clinicians typically start with:
• Small-frame adults (lower BSA): initial fills of 1.5–2.0 L, escalating gradually as tolerance is confirmed • Average-frame adults: the conventional 2.0–2.5 L standard exchange volume • Large-frame adults (higher BSA): fills of 2.5–3.0 L can often be used from the outset, since the larger abdominal cavity buffers the same volume to a lower relative pressure
In pediatric peritoneal dialysis, fixed-volume prescribing is inappropriate given the wide range of body sizes; dosing is instead scaled to body weight (mL/kg) or BSA (mL/m²), typically starting conservatively and increasing as the child demonstrates tolerance and growth.
Two adults can receive an identical 2.5 L fill and experience very different intra-abdominal pressures, because abdominal cavity capacity is not a fixed constant — it scales with body frame, prior abdominal surgeries, abdominal wall tone, and even parity in women. A small-framed patient given a "standard" 2.5 L fill may be pushed well past a comfortable pressure range, while a large-framed patient at the same volume may be under-dosed relative to their available peritoneal surface area, leaving clearance and ultrafiltration capacity on the table.
This is the rationale for expressing fill volume targets as body-size-scaled ranges rather than single numbers: the goal is to match dialysate volume to the individual's peritoneal surface area and cavity compliance, not to a population average.
Titration in practice is incremental and empirical: a new CAPD patient typically starts at a conservative fill volume for their body size, then volume is increased in steps of 200–500 mL every 1–2 weeks — provided the patient tolerates each step without new fullness, leak, or breathlessness — until the body-size-appropriate target range is reached.
Dwell time — the period dialysate remains in the abdomen between instillation and drain — determines how fully solutes equilibrate between blood and dialysate. Diffusion, ultrafiltration, and glucose absorption all evolve differently over the course of a dwell, and the Peritoneal Equilibration Test (PET) formally characterizes how quickly an individual patient's membrane transports solutes.
At the start of a dwell, fresh dialysate has near-zero concentration of urea, creatinine, and other uremic solutes, creating a steep concentration gradient across the peritoneal membrane. Diffusion is fastest early in the dwell and progressively slows as dialysate solute concentration rises toward the blood concentration — an exponential approach to equilibrium described by the dialysate-to-plasma (D/P) ratio.
• Small, fast-diffusing solutes (urea) approach equilibrium relatively quickly, often substantially equilibrated within 2–4 hours • Larger solutes (creatinine) equilibrate more slowly, typically requiring 4–8 hours to approach a plateau, depending on individual membrane transport characteristics • Once D/P approaches 1.0 for a given solute, further dwell time adds little additional diffusive clearance for that solute — the gradient has been exhausted
This means that beyond a patient-specific point, simply extending dwell time yields diminishing diffusive returns, and the prescription instead needs more exchanges or higher fill volumes to add clearance.
Unlike diffusion, ultrafiltration in standard glucose-based CAPD solutions depends on an osmotic gradient created by the dialysate glucose concentration (typically 1.5%, 2.5%, or 4.25% dextrose). This gradient is highest immediately after instillation and dissipates over the dwell as glucose is absorbed across the peritoneal membrane into the bloodstream.
The practical consequence is a characteristic ultrafiltration curve: net fluid removal rises early in the dwell, peaks (commonly around 2 hours for standard glucose strengths), then plateaus and can even reverse — fluid reabsorption back into the patient — during very long dwells as the osmotic gradient is lost and lymphatic reabsorption continues unopposed.
This reversal is particularly relevant for the long overnight dwell in CAPD: an 8–10 hour dwell with standard dextrose solution may achieve near-zero or even negative net ultrafiltration by the morning drain, whereas a shorter or icodextrin-based long dwell can sustain more consistent fluid removal.
Because diffusive clearance keeps rising (slowly) across a long dwell while ultrafiltration can peak and reverse, dwell time prescriptions often balance a mix of shorter, higher-glucose daytime exchanges optimized for ultrafiltration with one longer overnight dwell — sometimes using icodextrin — optimized to sustain fluid removal without glucose reabsorption reversal.
The CAPD prescription is not defined by fill volume alone — the number of exchanges performed each day multiplies with per-exchange fill volume to determine total daily dialysate volume, which in turn is the primary lever for total daily solute clearance and fluid removal.
For a fixed target of total daily dialysate volume, clinicians can reach that target with fewer, larger exchanges or more, smaller exchanges — and the choice has real physiological and lifestyle consequences:
• Fewer, larger exchanges (e.g., 3 exchanges of 3 L) reduce the number of manual exchange procedures a patient must perform each day — improving convenience and adherence — but each exchange carries a higher instantaneous intra-abdominal pressure • More, smaller exchanges (e.g., 5 exchanges of 1.8 L) keep IAP consistently lower and can improve tolerance in patients sensitive to fullness, but increase the daily burden of manual exchange procedures and the cumulative risk of peritonitis from more frequent catheter connections
A standard adult CAPD regimen commonly uses four exchanges per day: three daytime exchanges of several hours each, plus one long overnight dwell — balancing clearance, ultrafiltration, and the practical burden of manual exchanges around a normal daily routine.
The clinical adequacy target for peritoneal dialysis is most commonly expressed as weekly Kt/V urea — the fraction of total body urea distribution volume cleared per week, summing peritoneal and any residual native kidney clearance. International guidelines have historically targeted a weekly Kt/V of at least 1.7.
Because Kt/V accumulates across every exchange performed in a day, both the fill volume per exchange and the number of exchanges per day feed directly into total weekly clearance:
Weekly Kt/V ≈ (exchanges/day × fill volume × D/P ratio × 7) / urea distribution volume
This is why increasing either lever — a larger fill volume per exchange, or one additional exchange per day — can be used interchangeably (within tolerance limits) to raise total clearance toward an adequacy target, and why the "right" prescription is really a joint optimization over both variables rather than either one alone.
A patient not reaching their Kt/V adequacy target has two independent levers available: increase fill volume per exchange (constrained by IAP tolerance), or add an additional exchange per day (constrained by lifestyle burden and peritonitis exposure) — the choice between them is individualized to which constraint is less limiting for that patient.
CAPD prescribing is not a one-time calculation — it is an iterative process. Initial fill volume and exchange schedule, set from body size estimates, are refined over weeks to months based on how the individual patient actually tolerates and responds to dialysate, and periodically re-anchored to objective adequacy testing.
Between formal adequacy tests, the most immediate feedback on a CAPD prescription comes from the patient themselves. Symptoms tracked at each clinic visit and, ideally, self-monitored at home include:
• Abdominal fullness, bloating, or early satiety — suggesting fill volume may be approaching the patient's IAP tolerance ceiling • New back pain or exit-site/hernia bulging — a mechanical warning sign requiring volume reduction and evaluation • Breathlessness, especially when supine — may indicate diaphragmatic compromise from high IAP, particularly relevant in patients with reduced pulmonary reserve • Excessive or insufficient ultrafiltration — reported as unexplained weight gain, edema, or conversely symptomatic volume depletion
These reports directly inform incremental volume titration: symptoms of intolerance trigger a reduction or slower escalation, while an asymptomatic patient with an adequacy shortfall is a candidate for further volume or exchange-count escalation.
Subjective tolerance is necessary but not sufficient — prescriptions are periodically re-anchored to objective measurement:
• Peritoneal Equilibration Test (PET): characterizes an individual patient's membrane transport rate (low, low-average, high-average, or high transporter) by measuring D/P creatinine and dialysate glucose ratios over a standardized 4-hour dwell. High transporters equilibrate quickly and may benefit from shorter, more frequent exchanges; low transporters equilibrate slowly and may benefit from longer dwells to extract more clearance per exchange • Weekly Kt/V urea: the summary adequacy metric combining peritoneal and residual renal clearance; falling below target triggers a structured prescription review — fill volume, exchange number, dwell time, and dialysate glucose strength are all candidate levers • Ultrafiltration trend and residual renal function trend: declining residual kidney function over time typically requires compensatory increases in peritoneal dialysate dosing to maintain the same total clearance
The result is a closed loop: initial body-size-based prescription → tolerance monitoring → periodic objective testing → prescription adjustment → re-monitoring — repeated for as long as the patient remains on CAPD, since both membrane transport characteristics and residual renal function can evolve over time.
A useful mental model: fill volume and exchange count are adjusted for pressure/comfort tolerance first (a hard physiological ceiling), and dwell time and glucose strength are then tuned within that volume envelope to hit the clearance and ultrafiltration targets — rather than treating all four variables as freely interchangeable.